Background. Our objective was to assess differences in all-cause mortality, as well as AIDS and non-AIDS death rates, among patients started on antiretroviral therapy (ART) according to their geographical origin and ethnicity/race in Europe, Canada, and the United States.
administrative categories, have been wrongly used for inferring racial causality [18, 19] . The International Organization for Migration defines an international migrant as anyone who changes his/her country of usual residence for longer than a year [20] . Some migrants become part of established ethnic minorities, which may include recent migratory waves such as Caribbean communities in the United Kingdom. Besides, there are established minorities such as Romani (gypsies) in Europe and African Americans in the United States. First Nations people in Australia, Canada, and the United States have become minorities within these countries.
Few data are available on all-cause and cause-specific mortality following ART initiation according to geographical origin (GO) and ethnicity/race (E/R). Although migrants and ethnic minorities are not equivalent, numerous studies have combined them together as "vulnerable populations." The large datasets available through multicohort collaborations provide an opportunity to explore these questions. The ART Cohort Collaboration (ART-CC) collects information on the geographical origin and the ethnicity of large numbers of HIV-positive people from cohorts in Europe, Canada, and the United States. In this work, we aim to assess differences in all-cause mortality, as well as AIDS and non-AIDS death rates, among patients started on ART according to their GO and E/R in Europe, Canada, and the United States.
SUBJECTS AND METHODS

Study Population
We combined data from 19 cohorts in Europe and North America. The ART-CC has been previously described [21] . In brief, it includes patients with confirmed HIV infection aged ≥16 years who started ART while antiretroviral naive from 1998 onward. For these analyses, patients had to have information either on GO or E/R. Contributing cohorts have been approved by ethics committees or institutional review boards, use standardized methods of data collection, and schedule followup visits at least every 6 months. Access to healthcare and ART varied across cohorts; Europe and Canada have healthcare systems with universal access, whereas in the United States access to care and extent of healthcare coverage varies.
Variables and Definitions
Migrants were defined according to GO derived from information on country of birth and/or country of origin, nationality, and other surrogates. Information on GO was available for most (9/12) European, all Canadian (2/2), and 1 US (1/5) cohort.
In Europe, information on GO was available for 46 648 (85.2%) patients and was classified as follows: European countries; sub-Saharan Africa (SSA); Caribbean and South and Central America (LA); Northern Africa and Middle East (NAME); Asia (ASIA); and non-European Western countries (WEST). (The 2 last categories are combined as ASIA/WEST.) E/R data was available for some European (5/12), all Canadian (2/2), and all US (5/5) cohorts, and was classified as white, African American, Hispanic, First Nations, and Asian. We excluded patients whose E/R was "mixed" (n = 5) or "other" (n = 1053). In Canada, 1623 (54.2%) patients had information on GO, 1702 (56.8%) on E/R, and 1379 (46.1%) on both. Patients were classified according to E/R, (white, African American, First Nations, Asian, and Hispanic) and GO (Canadian and migrants). We excluded black (n = 4) and Asian Canadians (n = 4), because there were fewer than 5 deaths among these groups. In United States, valid data on E/R was available for 7759 patients (87.9%). Asians (n = 17) were excluded because there were fewer than 5 deaths.
Death and date of death were ascertained by cohorts through chart review and, in some, cross-checks with mortality registers. Cause of death was ascertained and classified centrally by ART-CC investigators in all but the Veterans Aging Cohort Study (VACS) cohorts and classified into AIDS deaths and non-AIDS deaths [22] . VACS obtained causes of death from the National Death Index using the International Classification of Diseases, Tenth Revision (ICD-10). Patients were considered lost to follow-up if there was a lag of >2 years between the last date the patient was known to be alive and the administrative censoring date, which varied between cohorts from 31 December 2006 to 31 December 2009. For the majority, the censoring date was 31 December 2009.
Statistical Analyses
Because of the different contexts, population composition, and healthcare delivery, we performed separate analyses for Europe, Canada, and the United States. Differences in demographic and clinical characteristics were assessed through Kruskal-Wallis tests for continuous variables and χ 2 tests for categorical variables. We used the Kaplan-Meier method to estimate the cumulative incidence of death by time since ART initiation. We calculated rates per 1000 person-years ( py) with 95% confidence intervals (95% CIs). Mortality hazard ratios from ART initiation were estimated using Cox proportional hazards models. Individuals not known to have died during the followup period were censored on the date at which death was ascertained or on the cohort-specific date for which follow-up was assumed to be complete, whichever arose first. Proportional hazards models on the subdistribution hazard were used to estimate subdistribution hazard ratios (sHRs) [23] for associations of geographical origin with AIDS and non-AIDS mortality; non-AIDS mortality was treated as a competing event for AIDS mortality analyses, and vice versa. We used 2 methods to test the proportionality of hazards for overall mortality and subhazards for AIDS and non-AIDS mortality analyses: (1) , ≥500 cells/μL) and HIV load (<100 000, ≥100 000 copies/mL) at ART initiation. We explored interactions by sex, transmission category, and age at ART. Wald tests were used to derive P values. We examined immunological, virological, and clinical status of the patients lost to follow-up by GO and E/R. All statistical analyses were performed using Stata software (version 11.0, College Station, Texas).
RESULTS
Sociodemographic Characteristics
Of 46 648 patients from European cohorts, Europeans accounted for 35 113 (75.3%) of patients; 23.3% were women (Table 1) . Among migrants, the commonest GO was SSA (n = 7592, 60.9% women); the second commonest GO was LA (n = 2364, 38.5% women); the third commonest GO was NAME (n = 781, 26.4% women); and the fourth commonest was ASIA/WEST (n = 798, of whom 698 were Asians and 46.7% women). Of 1371 patients from Canadian cohorts, the majority were white Canadians (859 [62.7%]), followed by First Nations people (n = 205 [14.9%]) and migrants (n = 307 [22.4%]) ( Table 2 ). Of 7742 patients from US cohorts, the commonest E/ R was African American (n = 4295 [55.5%]), white (n = 2934 [37.9%]), and Hispanic (n = 513 [6.6%]; Table 2 ).
Mortality
Overall, 55 602 patients were followed for a median of 4 years (interquartile range [IQR], 2-7) after ART initiation, and 4270 died. In Europe, GO was associated with mortality in crude and adjusted analyses ( Figure 1A , Table 3 Figures 1C and 2 ): mortality was higher in African Americans compared to whites. We found little evidence of nonproportional hazards comparing different groups in Europe or Canada (P > .05). However, in US patients, AHRs Figure 1 . Cumulative incidence of death from antiretroviral initiation according to geographical origin and race/ethnicity in Europe (A), Canada (B ), and the United States (C ). Abbreviations: ASIA/WEST, Asia/non-European Western countries; cART, combination antiretroviral therapy; LA, Caribbean and South and Central America; NAME, Northern Africa and Middle East; RE, race/ethnicity; SSA, sub-Saharan Africa. 
AIDS-Related and Non-AIDS-Related Causes of Death
Information on cause of death was available for 2119 patients in Europe, 131 in Canada, and 1585 in the United States (Table 4 ). This accounted for 85%, 91%, and 93% of all deaths, respectively. In Europe, patients of European origin had higher non-AIDS (6.4 per 1000 py) than AIDS (4.0 per 1000 py) mortality rates. AIDS mortality rates in patients from SSA were similar to those of Europeans (3.4 per 1000 py), but non-AIDS mortality rates were lower (2.5 per 1000 py). The highest rates of non-AIDS deaths in Europeans were non-AIDS malignancies (n = 284, 1.7 per 1000 py), liver disease (n = 163, 0.9 per 1000 py), cardiovascular disease (n = 161, 0.9 per 1000 py), and non-AIDS infections (n = 151, 0.9 per 1000 py). The corresponding number of events and rates in migrants from SSA were 19 (0.6 per 1000 py), 9 (0.3 per 1000 py), 19 (0.6 per 1000 py), and 20 (0.6 per 1000 py), respectively. Death rates due to external causes and drug abuse were also lower in migrants from SSA compared to Europeans. Figure 1A) . However, for non-AIDS mortality there was evidence of nonproportional hazards as the adjusted sHR for nonEuropeans decreased over time (Supplementary Figure 1B) .
First Nations people had higher rates of AIDS and non-AIDS mortality than white Canadians (Table 4) , and also had high rates of non-AIDS mortality (20.3 per 1000 py). The highest non-AIDS mortality rates in First Nations people were due to substance abuse (n = 6; 6.1 per 1000 py), cardiovascular disease (n = 4; 4.1 per 1000 py), non-AIDS-defining infections (n = 3; 3.1 per 1000 py), and external causes (n = 3; 3.1 per 1000 py).
In the United States, compared to whites, African Americans had higher AIDS (adjusted sHR, 1.22 [95% CI, 1.09-1.36]) and non-AIDS (adjusted sHR, 1.11 [95% CI, 1.04-1.18]) mortality. Hispanics also had higher AIDS mortality (adjusted sHR, 1.23 [95% CI, 1.11-1.37]) than whites. For both African Americans and Hispanics, sub-hazard ratios for AIDS mortality increased with increasing time since ART ( Figure 3A) . Subhazard ratios for non-AIDS mortality increased over time in African Americans but not in Hispanics ( Figure 3B ). The adjusted sHRs were higher in Hispanics than in whites in the first 2 years after ART to become lower after the fifth year after ART ( Figure 3B ).
Loss to Follow-up
Loss to follow-up (LTFU) differed between regions (P < .001): Europe 24.0%, Canada 8.9%, and United States 6.7%. In Europe, rates of LTFU differed by GO (P < .001): Europe Figure 3 . A, Adjusted subdistribution hazard ratios (sHRs) for AIDS mortality according to race/ethnicity in the United States. B, Adjusted sHRs for non-AIDS mortality according to race/ethnicity in the United States. Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IDU, injection drug user; MSM, men who have sex with men; sHR, subdistribution hazard ratio.
23.6%, SSA 26.5%, LA 23.7%, NAME 24.7%, ASIA/WEST 15.4%. Among patients lost to follow-up, there were significant differences by GO in the median CD4 cell counts (cells/mL) in the 6 months prior to the last date in which death was ascertained (P < .001): 410 (IQR, 252-600) in Europeans, 338 (IQR, 217-489) in SSA, 351 (IQR, 225-532) in LA, 358 (IQR, 210-523) in NAME, and 402 (IQR, 206-547) in ASIA/WEST. In Canada, no significant differences in LTFU rates by E/R and GO were found (P = .20): white Canadian 8.3%, First Nations 12.2%, migrants 8.5%. Among patients lost to followup, no significant differences by E/R and GO in the median CD4 cell counts (cells/mL) in the 6 months prior to the last date in which death was ascertained were found (P = .21): 390 (IQR, 230-545) in white Canadians, 231 (IQR, 90-440) in First Nations people, and 361 (IQR, 200-691) in migrants.
In the United States, the percentage of LTFU differed by E/R (P < .001): whites 8.6%, African Americans 5.4%, and Hispanics 7.2%. Among patients lost to follow-up, no significant differences by E/R in the median CD4 cell counts in the 6 months prior to the last date in which death was ascertained were found (P = .16): 388 (IQR, 223-573) in whites, 318 (IQR, 184-531) in African Americans, and 326 (IQR, 264-516) in Hispanics.
DISCUSSION
We report striking differences in the associations between ethnicity and geographic origin with mortality after initiation of ART in Europe, the United States, and Canada. HIV-positive migrants from SSA and ASIA/WEST living in Europe had lower mortality following ART than HIV-positive, predominantly white Europeans, mainly attributable to lower non-AIDS mortality rates. By contrast, HIV-positive First Nations people in Canada, and African Americans in the United States, had higher mortality after ART than did white Canadians and Americans-although for First Nations in Canada, estimates were imprecise. In Canada, higher mortality was explained by higher non-AIDS mortality rates among First Nations people, probably attributable to substance use and underlying socioeconomic inequalities. Mortality rates also appeared to be lower in other migrant groups (North Africa and the Middle East in Europe and all migrants in Canada).
The lower mortality experienced by most migrant groups in Europe and Canada after ART initiation, compared to predominantly white nonmigrants, may have various explanations. Similar to the "healthy worker" effect, as the majority of migrants travel from developing to industrialized countries seeking work, they tend to have lower mortality rates than the general population [15] . This effect may be further exaggerated by the sickest migrants returning home to die ("unhealthy remigration" or "salmon bias"), prompted by their inability to remain in the country when they lose their jobs due to poor health and lack of social support networks [24] . It is unlikely that "salmon bias" played an important role in this study, because HIV care is more restricted and HIV-associated stigma high in most migrants' countries of origin [25] , although we have no direct data to support this. In spite of lower incomes, migrants from developing countries tend to maintain, in their countries of destination, the healthier diet and lifestyles from less affluent societies [26] , although length of residence has been described to be associated with increases in sedentary lifestyles and poorer eating habits [27, 28] . Although this is well established for general population migrants, it is hard to extrapolate these findings to HIV-positive migrants, the majority of whom are relatively young. Further, for those from SSAalthough no firm data are available-length of stay in Europe is short [29] , so exposure to acculturation processes is less likely to have had an impact. The lower non-AIDS mortality rates of migrants in Europe observed in our study support the hypothesis of lower background mortality. Migrants from SSA had lower rates of non-AIDS mortality, notably non-AIDS defining cancers, the commonest non-AIDS related death in Europeans in our study as well as in numerous others [24, 30, 31] . Arnold et al reviewed 37 studies from EU countries and report that migrants of unknown HIV status from non-Western countries were more likely to develop infectious disease-related cancers and less likely to develop those causally linked to lifestyles of affluent societies [31] [32] [33] . These findings are consistent with the variations in hepatitis B and C epidemiology of HIV-positive populations by geographic origin [34] . These nativity differentials have been also described in the United States by Singh and Hiatt for major cancers, cardiovascular diseases, diabetes, respiratory diseases, unintentional injuries, and suicide, with immigrants experiencing generally lower mortality than US-born people [35] .
In our study, losses to follow-up in Europe were slightly higher in patients from SSA compared to Europeans and those lost to follow-up had lower CD4 cell counts; thus mortality rates in SSA may be underestimated. By contrast, migrants from Asia had better follow-up rates than Europeans. Although there may be some underestimation of mortality in migrants in Europe, this is unlikely to fully explain the differences in mortality rates that we observed.
HIV-positive migrants from SSA in Europe have lower mortality from date of seroconversion than native HIV-positive patients [7] . Previous studies have reported similar, or slightly better, HIV progression rates in migrants from SSA in Europe and lower CD4 cell count declines [36, 37] . Some of these studies have linked these better disease profiles to the higher prevalence of non-B subtypes but no firm data are available. Data from HIV-positive migrants other than those from SSA were scant. Here, we report also lower mortality of Asian migrants in Europe and some evidence of lower mortality for those from North Africa and the Middle East. To our knowledge, no previous studies have reported mortality estimates in HIV-positive migrants of GO other than SSA.
The higher mortality of HIV-positive First Nations people in Canada and African Americans in the United States is likely to reflect social and health inequalities, including cultural discrimination, higher unemployment, lower incomes, higher rates of imprisonment, lack of access to adequate healthcare, and higher ART discontinuation rates [38] [39] [40] [41] [42] . Both populations have higher rates of HIV infection than the general population, but are less likely to reap the benefits of ART. First Nations people had slightly higher rates of LTFU, which occurred at lower CD4 counts. This may lead to underestimation of overall death rates in this population.
Misclassification of GO and E/R was inevitable. Providing that such misclassification is nondifferential (unrelated to underlying prognosis), resulting bias will be toward the null, such that true differences are likely to be larger than those we have observed. Both GO and E/R encompass biological, societal, and behavioral issues that cannot be separated, as we lack subtype and genetic data, smoking and health-seeking behaviors and socioeconomic status. Misclassification of cause of death was minimized by the ART-CC through an ad hoc committee [22, 43] . The ICD-10 may overestimate HIV/AIDS-associated deaths at the expense of cirrhosis of viral cause or unknown etiology [44] .
Finally, the inferences made from this study are applicable to patients who have already successfully accessed health services and are not representative of all HIV-infected patients. Participants in ART-CC cohorts are not fully representative of patients in their countries, and transmission category was unknown in half of US patients.
In conclusion, mortality rates following initiation of ART in HIV-positive migrants and established ethnic minorities in Europe and North America differ from those in predominantly white nonmigrants. The former have better survival, probably reflecting healthy migrant effects, whereas the latter fare worse, reflecting health and societal inequality.
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